IXICO Plc engages in the provision of technology-enabled specialty services to the global biopharmaceutical industry. The firm is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. The company advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Follow-Up Questions
IXICO PLC (PHYOF)의 PER은 얼마입니까?
IXICO PLC의 PER은 N/A입니다
IXICO PLC의 CEO는 누구입니까?
Mr. Giulio Cerroni은 2017부터 회사에 합류한 IXICO PLC의 Chief Executive Officer입니다.
PHYOF 주식의 가격 성능은 어떻습니까?
PHYOF의 현재 가격은 0이며, 전 거래일에 decreased 0% 하였습니다.
IXICO PLC의 주요 사업 주제나 업종은 무엇입니까?
IXICO PLC은 Life Sciences Tools & Services 업종에 속하며, 해당 부문은 Health Care입니다
IXICO PLC의 시가총액은 얼마입니까?
IXICO PLC의 현재 시가총액은 $0입니다
IXICO PLC는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 IXICO PLC에 대한 분석 평가를 실시했으며, 이는 4명의 강력한 매수, 4명의 매수, 1명의 보유, 0명의 매도, 그리고 4명의 강력한 매도를 포함합니다
